Alzheimer’s disease and related cognitive decline
Research activity is centred on Alzheimer’s disease, late-onset Alzheimer disease, sporadic early-onset Alzheimer disease, and broader dementia syndromes, with emphasis on brain imaging markers that track early pathological change.
- Alzheimer’s disease
- Late onset Alzheimer disease
- Sporadic early onset Alzheimer disease
- Dementia
Imaging-focused work includes amyloid deposition, tau aggregates, and glucose metabolism in cognitively affected and at-risk populations.
Preclinical and familial neurodegeneration
The sponsor also studies inherited and early-stage neurodegenerative conditions, including autosomal dominant Alzheimer’s disease, with interest in biological changes that appear before overt clinical symptoms.
- Autosomal dominant Alzheimer’s disease
- Early neurodegenerative change
- Brain biomarker profiling
Work in this area is aligned with cohorts designed to detect subtle shifts in amyloid burden and tau pathology across the Alzheimer’s continuum.
Vascular cognitive disorders
Clinical research extends to CADASIL, reflecting interest in hereditary small-vessel disease and its contribution to cognitive impairment, white matter injury, and progressive neurological decline.
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
- Subcortical ischemic disease
- Leukoencephalopathy
This area connects vascular brain injury with broader mechanisms of dementia and neurodegeneration.
Molecular brain imaging
Funded studies place strong focus on PET imaging of amyloid, tau, and synaptic or metabolic markers to map disease-related changes across Barcelona-based cohorts.
- PET biomarkers
- Amyloid imaging
- Tau imaging
- Metabolic brain imaging
These investigations support characterization of disease progression in neurodegenerative disorders and related clinical phenotypes.
